Axiom’s Hong Kong Bet, Latigo’s Positive Phase II, and Base Editors for Huntington’s

Phase 2positivePositive

AI Analysis

Summary

Latigo reported positive Phase II results while Axiom announced expansion plans in Hong Kong. The episode also covered scientific developments in base editing for Huntington's disease and potential fibromyalgia research.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Latigo reported positive Phase II results

Importance:5/10

Sentiment:

0.50

Phase 2 dataHuntington's diseasebase editingfibromyalgiaHong Kong expansion

Related Companies

$LTGO

Read the original article

Published by GEN - Genetic Engineering & Biotech News on July 31, 2026 4:00 PM

Read Original